Altamira Therapeutics .(CYTO) - 2023 Q4 - Earnings Call Presentation

24,277 15,395 984,191 Confidential 18 • sale of equity or convertible debt securities altamira therapeutics Business Update & Full Year 2023 Earnings Call April 10, 2024 • Thomas Meyer, Ph.D. • Covadonga Pañeda, Ph.D. NASDAQ: CYTO Forward-Looking Statements Update NASDAQ: CYTO Transitioning to Become a Focused RNA Delivery Company • Substantially reduced operating expenses / cash burn 5 6 • Insertion of peptide into adeno-associated virus (AAV) vectors significantly enhances cell transduction 'Picks and Sho ...